Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.39 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.39 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15224107 | 0.90 | CYP2D6 (0.58) | TDP1CYP2D6SMN1; SMN2ALDH1A1BACE1 | |
| SCHEMBL1380295 | 0.82 | — | — | |
| SCHEMBL9498033 | 0.81 | TDP1 (0.39) | TDP1FAAHCYP2D6SMN1; SMN2CNR1 | |
| SCHEMBL9499570 | 0.81 | TDP1 (0.39) | TDP1FAAHCYP2D6SMN1; SMN2CNR1 | |
| SCHEMBL9795106 | 0.81 | TDP1 (0.39) | TDP1FAAHCYP2D6SMN1; SMN2CNR1 | |
| SCHEMBL6938019 | 0.81 | TDP1 (0.59) | TDP1FAAHCYP2D6SMN1; SMN2CNR1 | |
| SCHEMBL15224299 | 0.79 | CYP2D6 (0.54) | TDP1FAAHCYP2D6SMN1; SMN2CNR1 | |
| SCHEMBL1751752 | 0.78 | TDP1 (0.50) | TDP1FAAHCYP2D6SMN1; SMN2CNR1 | |
| SCHEMBL1690847 | 0.78 | FAAH (0.57) | TDP1FAAHSMN1; SMN2CNR1CNR2 | |
| SCHEMBL4431884 | 0.76 | TDP1 (0.48) | TDP1FAAHCYP2D6SMN1; SMN2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339687-A1 | 4-6-DIPHENYL PYRIDINE DERIVATIVES AS ANTIINFLAMMATORY AGENTS | Bayer Aktiengesellschaft (DE) | 2003-09-03 | — | — | EP | claimed |
| WO-2002044153-A1 | 4-6-DIPHENYL PYRIDINE DERIVATIVES AS ANTIINFLAMMATORY AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-06-06 | — | — | WO | claimed |
| EP-3169666-B1 | SUBSTITUTED AZASPIRO(4.5)DECANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2018-06-06 | — | — | EP | disclosed |
| US-7968584-B2 | Substituted arylpyrazoles | PFIZER INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7645786-B2 | 1-aryl-4-cyclopropylpyrazoles with at least one fluorine attached to the cyclopropyl ring; parasiticides; fleas; extended duration of action for at least 28 days | PFIZER INC. (US) | 2010-01-12 | — | — | US | disclosed |
| EP-2102167-A2 | SUBSTITUTED ARYLPYRAZOLES | Pfizer Limited (GB) | 2009-09-23 | — | — | EP | disclosed |
| US-20090186924-A1 | SUBSTITUTED ARYLPYRAZOLES | PFIZER INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-7538134-B2 | Substituted arylpyrazoles | PFIZER INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080176865-A1 | SUBSTITUTED ARYLPYRAZOLES | PFIZER LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
| WO-2008072053-A2 | SUBSTITUTED ARYLPYRAZOLES | PFIZER LIMITED (GB) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008072077-A2 | COMBINATION OF 1-ARYL-4-CYCLOPROPYLPYRAZOLES WITH ANTHELMINTIC AGENT FOR PARASITIC INFESTATION | PFIZER LIMITED (GB) | 2008-06-19 | — | — | WO | disclosed |
| US-20070149464-A1 | COMBINATION | PFIZER INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20060287365-A1 | Substituted arylpyrazoles | ZOETIS LLC | 2006-12-21 | — | — | US | disclosed |
| WO-2006134468-A1 | SUBSTITUTED ARYLPYRAZOLES FOR USE AGAINST PARASITITES | PFIZER LIMITED (GB) | 2006-12-21 | — | — | WO | disclosed |
| EP-1450811-A4 | 2-ARYL PYRROLOPYRIMIDINES FOR A1 AND A3 RECEPTORS | OSI PHARM INC (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1347980-A4 | COMPOUNDS SPECIFIC TO ADENOSINE-A1,-A2A, AND- A3-RECEPTOR AND USES THEREOF | OSI PHARM INC (US) | 2005-02-09 | — | — | EP | disclosed |
| EP-1450811-A2 | 2-ARYL PYRROLOPYRIMIDINES FOR A1 AND A3 RECEPTORS | Osi Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| EP-1347980-A1 | COMPOUNDS SPECIFIC TO ADENOSINE-A1,-A2A, AND- A3-RECEPTOR AND USES THEREOF | OSI Pharmaceuticals, Inc. (US) | 2003-10-01 | — | — | EP | disclosed |
| WO-2003048120-A2 | 2-ARYL PYRROLOGPYRIMIDINES FOR A1 AND A3 RECEPTORS | OSI PHARMACEUTICALS, INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2002057267-A1 | COMPOUNDS SPECIFIC TO ADENOSINE A1, A2A, AND A3 RECEPTOR AND USES THEREOF | OSI PHARMACEUTICALS, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176865-A1 | SUBSTITUTED ARYLPYRAZOLES | CYP3A4, CYP3A43, CYP4B1 | TDP1 3554/4885FAAH 2229/4885CYP2D6 13/4885 |
| US-20060287365-A1 | Substituted arylpyrazoles | CYP3A4, CYP3A43, CYP4B1 | TDP1 3554/4885FAAH 2229/4885CYP2D6 13/4885 |
| US-20090186924-A1 | SUBSTITUTED ARYLPYRAZOLES | CYP3A4, CYP3A43, CYP4B1 | TDP1 3554/4885FAAH 2229/4885CYP2D6 13/4885 |
| US-20070149464-A1 | COMBINATION | PIGO, EPX, PIGS | TDP1 4609/4885FAAH 699/4885CYP2D6 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.